(Q46561624)

23 December 2017

title

Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand (English)

1 reference

23 December 2017

0 references

1 reference

1 reference

2

Simran Maggo

1 reference

23 December 2017

Ruth Savage

4

object named as

Ruth Savage

1 reference

23 December 2017

author name string

Mira Harrison-Woolrych

1

1 reference

23 December 2017

Ming Tan

3

1 reference

23 December 2017

Janelle Ashton

5

1 reference

23 December 2017

publication date

1 January 2012

1 reference

23 December 2017

published in

Drug Safety

1 reference

23 December 2017

volume

35

1 reference

23 December 2017

issue

1

1 reference

23 December 2017

page(s)

33-43

1 reference

23 December 2017

https://scigraph.springernature.com/pub.10.2165/11597690-000000000-00000

exact match

0 references

cites work

Varenicline for tobacco dependence

1 reference

https://api.crossref.org/works/10.2165%2F11597690-000000000-00000

Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597690-000000000-00000

Bupropion and other non-nicotine pharmacotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597690-000000000-00000

Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597690-000000000-00000

Varenicline in smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597690-000000000-00000

A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597690-000000000-00000

A double-blind study evaluating the long-term safety of varenicline for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597690-000000000-00000

Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597690-000000000-00000

Efficacy and safety of varenicline for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597690-000000000-00000

Psychiatric adverse events associated with varenicline: an intensive postmarketing prospective cohort study in New Zealand

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597690-000000000-00000

Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597690-000000000-00000

Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597690-000000000-00000

The New Zealand Intensive Medicines Monitoring Programme.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597690-000000000-00000

Adverse drug reactions: definitions, diagnosis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597690-000000000-00000

Adverse drug reactions. A critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597690-000000000-00000

Cigarette smoking: an undertreated risk factor for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597690-000000000-00000

Public health importance of triggers of myocardial infarction: a comparative risk assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597690-000000000-00000

Angina pectoris I. A variant form of angina pectoris

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597690-000000000-00000

Neurons can maintain multiple classes of nicotinic acetylcholine receptors distinguished by different subunit compositions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597690-000000000-00000

Clinical impact of selective spasm provocation tests: comparisons between acetylcholine and ergonovine in 1508 examinations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597690-000000000-00000

Hypertension, stroke, and endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597690-000000000-00000

Cardiovascular effects of activation of central alpha7 and alpha4beta2 nAChRs: a role for vasopressin in anaesthetized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597690-000000000-00000

Central nicotinic receptors, neurotrophic factors and neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597690-000000000-00000

Purinergic signalling in autonomic control

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597690-000000000-00000

Baroreceptor reflex pathways and neurotransmitters: 10 years on.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597690-000000000-00000

The sympathetic control of blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597690-000000000-00000

Arrhythmic cardiac arrest due to isolated coronary artery spasm: long-term outcome of seven resuscitated patients

21 January 2018

1 reference

12 December 2020

Pharmacovigilance in New Zealand: the role of the New Zealand Pharmacovigilance Centre in facilitating safer medicines use.

1 reference

12 December 2020

Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction

1 reference

12 December 2020

Angina pectoris. I. A variant form of angina pectoris; preliminary report

1 reference

12 December 2020

[Significance of coronary risk factors and coronary arteriosclerosis for coronary vasospasm]

1 reference

12 December 2020

Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation

1 reference

12 December 2020

Life-threatening ventricular arrhythmias in patients with silent myocardial ischemia due to coronary-artery spasm

1 reference

12 December 2020

Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up

1 reference

12 December 2020

Cigarette smoking is a major risk factor for coronary spasm

1 reference

12 December 2020

Hypertension and myocardial infarction

1 reference

12 December 2020

Functional organization of central pathways regulating the cardiovascular system

1 reference

12 December 2020

Influence of cigarette smoking on human autonomic function

1 reference

12 December 2020

Systematic Assessment of Patients With Unexplained Cardiac Arrest

1 reference

12 December 2020

10.2165/11597690-000000000-00000

Identifiers

DOI

1 reference

23 December 2017

Dimensions Publication ID

1053131018

0 references

1 reference

23 December 2017